Vascazen has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles
Pivotal Therapeutics, a speciality pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, has presented the cardio-protective effects of Pivotal's unique Omega-3 formulation commercialised as Vascazen at the 2014 Annual Scientific Meeting of the European Society of Cardiology (ESC) Congress 2014 in Barcelona, Spain, by Rasul et al. from the Laboratory of Biophotonics and Pharmacology of the University of Strasbourg, France.
The presented poster, entitled 'Chronic oral intake of the omega 3 optimized formulation EPA:DHA 6:1 protects against angiotensin II-induced hypertension and endothelial dysfunction in rats', indicated that chronic intake of Vascazen's EPA:DHA 6:1 prevented the development of hypertension and endothelial dysfunction in a rodent model. The vasoprotective and antihypertensive effects of Vascazen is mediated by an improvement of both the nitric oxide and the EDH-mediated relaxations as well as a reduction of endothelium-dependent contractile response.
'These findings show that formulation, purity and dose plays a significant role in biological activity,' said Dr George Jackowski, Chief Scientific Officer. 'Until now, many cardiologists believed that all Omega-3s had similar vasodilatory effects, regardless of formulation.
'We are very pleased to have had this opportunity to educate the attendees of the ESC Congress about the unique Vascazen EPA:DHA 6:1 formulation and its proven clinical superiority over other existing commercial products in the marketplace in terms of sustained coronary vasodilation.'
Vascazen is currently available in the US as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. It is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both US and foreign patents.
Vascazen has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. Vascazen's results were achieved with a dose of 3g of EPA and DHA per day of a prescription grade, high purity, uniquely formulated Omega-3.